Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Atossa Genetics Inc (ATOS)

Atossa Genetics Inc (ATOS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,532
  • Shares Outstanding, K 10,395
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,240 K
  • 60-Month Beta 2.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.83 +36.07%
on 09/04/20
2.95 -15.59%
on 09/01/20
-0.14 (-5.32%)
since 08/28/20
3-Month
1.83 +36.07%
on 09/04/20
5.08 -50.98%
on 08/03/20
-1.44 (-36.64%)
since 06/29/20
52-Week
0.75 +229.80%
on 03/12/20
5.08 -50.98%
on 08/03/20
+0.46 (+22.66%)
since 09/27/19

Most Recent Stories

More News
Atossa Therapeutics To Present at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit on September 22, 2020

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus...

MHMNF : 54.5000 (unch)
ATOS : 2.49 (+5.51%)
Atossa Therapeutics Receives Second Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus...

ATOS : 2.49 (+5.51%)
Physician-Scientist Dr. Steven Quay's "Stay Safe: A Physician's Guide to Survive Coronavirus" Reaches #1 on Five Amazon Bestsellers Lists

, /PRNewswire/ -- Renowned physician-scientist Dr. , MD, PhD, CEO of Atossa Therapeutics, Inc. (NASDAQ: ATOS) new book "," is officially number one on five Amazon New Release Bestseller lists: Viral...

ATOS : 2.49 (+5.51%)
Physician-Scientist Dr. Steven Quay Shares Back-to-School Tips To Stay Safe and Survive Coronavirus

, /PRNewswire/ -- Renowned physician-scientist Dr. , MD, PhD, CEO of Atossa Therapeutics, Inc. (NASDAQ: ATOS) is offering a simple tip for making your cloth Covid-19 face mask more effective.  The technique...

ATOS : 2.49 (+5.51%)
Atossa Therapeutics Announces Positive Interim Safety Assessment of First Group of Participants in Clinical Study of AT-301 Nasal Spray Being Developed for COVID-19

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus...

ATOS : 2.49 (+5.51%)
LD Micro - 360 Companies Set to Present this Week

LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

ACRX : 1.4800 (-3.27%)
ACER : 3.10 (+12.73%)
ACU : 22.67 (+2.81%)
AT.VN : 1.610 (-0.62%)
AEY : 1.8995 (+0.50%)
ADIL : 1.9400 (+37.59%)
ADTX : 1.8500 (+3.35%)
ADXS : 0.4217 (+8.13%)
AEHR : 1.4200 (unch)
AIM : 2.16 (-1.82%)
AIRI : 1.1799 (+2.60%)
ALIM : 5.24 (+2.54%)
ALJJ : 0.7388 (+3.62%)
ALLT : 9.18 (+2.46%)
ARCT : 41.57 (+1.27%)
AREC : 1.4500 (-5.23%)
AMS : 1.94 (-6.28%)
ANVS : 4.90 (+9.13%)
APEN : 1.6800 (+21.74%)
APM : 7.7400 (+534.43%)
AQMS : 0.9466 (+1.75%)
AQB : 4.52 (-5.04%)
ARTL : 0.9300 (+16.26%)
ARHH : 0.8000 (unch)
ATOM : 10.73 (+2.98%)
ATOS : 2.49 (+5.51%)
AUTO : 3.18 (-1.24%)
AYRO : 3.06 (+6.99%)
AZRX : 0.7218 (-2.46%)
BELFA : 11.67 (+8.56%)
BCDA : 2.26 (-0.88%)
BIOC : 4.46 (+2.29%)
BHTG : 1.2289 (-2.47%)
BIOL : 0.2753 (-1.68%)
BKEP : 1.5300 (+4.08%)
ATDS : 0.0091 (+10.98%)
ASUR : 7.49 (+1.90%)
BEER.VN : 0.055 (-8.33%)
ANY : 2.55 (-3.04%)
New COVID-19 Survival Manual Offers Tips from Renowned Physician Scientist to Keep You and Your Family Healthy During the Pandemic

, /PRNewswire/ -- A new book from Dr. , MD, PhD offers life-saving tips for navigating the deadly coronavirus pandemic and will provide a blueprint for how to keep you and your family safe during the...

ATOS : 2.49 (+5.51%)
Atossa Therapeutics to Present at the LD Micro 500 Virtual Conference on September 4, 2020

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus...

ATOS : 2.49 (+5.51%)
Atossa Therapeutics Announces Enrollment and Dosing Completed in First Group of Healthy Participants in Clinical Study of AT-301 Nasal Spray Being Developed for Treatment of COVID-19

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus...

ATOS : 2.49 (+5.51%)
Atossa Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus...

ATOS : 2.49 (+5.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade ATOS with:

Business Summary

Atossa Genetics Inc. is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. The Company's diagnostic tests consist of medical devices which can collect fluid samples from the breast milk ducts. It is also conducting...

See More

Key Turning Points

2nd Resistance Point 2.49
1st Resistance Point 2.42
Last Price 2.49
1st Support Level 2.31
2nd Support Level 2.27

See More

52-Week High 5.08
Fibonacci 61.8% 3.43
Fibonacci 50% 2.92
Last Price 2.49
Fibonacci 38.2% 2.41
52-Week Low 0.75

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar